Helix BioPharma Corp. Advances Despite Filing Delay

TipRanksMay 11 02:07

Helix BioPharma Corp. Progresses Amid Delays

TipRanksApr 13 07:37

Canadian Investment Regulatory Organization Trade Resumption - HBP

Stockhouse Apr 1 21:11

Helix BioPharma Corp. Secures New Funding

TipRanksMar 29 07:37

Canadian Investment Regulatory Organization Trading Halt - HBP

Stockhouse Mar 29 05:14

Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results

Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2024 first quarter results for the period ending October 31, 2023.

Stockhouse Dec 15, 2023 06:00